A paper by Meyer et al. (2020) has a nice summary of potential mechanisms through which the presence of COVID-19 could impact clinical trial results.
![](https://www.healthcare-economist.com/wp-content/uploads/2024/02/covid-1.png)
What should a researcher do when a clinical trial is impacted by COVID-19? Here are some analysis considerations.
![](https://www.healthcare-economist.com/wp-content/uploads/2024/02/COVID-3-1024x358.png)
The full article is interesting throughout.